| Mar 28 |
Nexalin Technology Announces Positive Results of Clinical Study Validating its Gen-2 tACS Device for Reducing Pain Among Veterans with Mild Traumatic Brain Injury at University of California, San Diego
|
| Mar 14 |
Nexalin Technology commences sales of gen-2 neurostimulation device in Oman
|
| Mar 14 |
Nexalin Technology Commences Sales of Gen-2 Neurostimulation Device to New Mental Health Center in Oman Dedicated to Nexalin’s Technology
|
| Mar 13 |
Nexalin Technology Announces Poster Presentation at “State of the Technology Meeting: Neurotrauma Diagnosis, Monitoring, and Assessment”
|
| Mar 6 |
Nexalin Technology Announces Positive Results from Clinical Study of its Gen-2 tACS Device for Treating Adult Patients with Chronic Insomnia
|
| Feb 8 |
Nexalin Technology Announces Regulatory Approval in Oman for Gen-2 Neurostimulation Device
|
| Jan 23 |
Nexalin Technology Awarded Key Patent Related to its Non-Invasive, Frequency-Based Deep-Brain Stimulation Device – the Transcranial Alternating Current Dynamic Frequency Stimulation (TACS) System
|
| Jan 11 |
Nexalin Technology Unveils Next-Generation HALO™ Clarity
|
| Dec 18 |
Nexalin Technology Reports Significant Positive Results of Clinical Study Supporting the Therapeutic Benefits of its Gen-2, 15 Milliamp Neurostimulation Device on Treatment-Resistant Depression
|
| Nov 28 |
Why SpringWorks Shares Are Trading Higher By Around 14%; Here Are 20 Stocks Moving Premarket
|
